Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 9/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2547266 | 0.92 | ABL1 (0.37) | NPC1RAB9AABL1 | |
| SCHEMBL1841257 | 0.85 | CASP3 (0.50) | NPC1RAB9AABL1CASP3SENP8 | |
| SCHEMBL2537528 | 0.84 | CSNK1D (0.38) | NPC1RAB9AKDM4EMETMEN1 | |
| SCHEMBL2546149 | 0.83 | LMNA (0.39) | MEN1KMT2A | |
| SCHEMBL2544861 | 0.83 | ACHE (0.36) | NPC1RAB9AKDM4EMEN1KMT2A | |
| SCHEMBL2540801 | 0.82 | PKM (0.36) | NPC1RAB9AKDM4EMEN1KMT2A | |
| SCHEMBL1829464 | 0.82 | WNT3A (0.36) | NPC1RAB9AKDM4EABL1MEN1 | |
| SCHEMBL2546977 | 0.82 | TRPV1 (0.38) | — | |
| SCHEMBL2540184 | 0.82 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL2546951 | 0.82 | BCHE (0.41) | KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | US | claimed |
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | US | disclosed |
| CN-102159577-A | Imidazo [1,2-a ] pyrimidine derivatives, process for their preparation, their use as medicaments, pharmaceutical compositions and as MET inhibitors | SANOFI AVENTIS | 2011-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | TPMT, MET, PAICS | NPC1 1726/4885RAB9A 2193/4885KDM4E 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.